Residual disease is a strong prognostic marker in patients with acute lymphoblastic leukaemia with chemotherapy-refractory or relapsed disease prior to allogeneic stem cell transplantation

Momoko Nakamura, Yasuyuki Arai, Shigeki Hirabayashi, Tadakazu Kondo, Noriko Doki, Naoyuki Uchida, Takahiro Fukuda, Yukiyasu Ozawa, Masatsugu Tanaka, Masashi Sawa, Yuta Katayama, Yoshinobu Kanda, Souichi Shiratori, Hirohisa Nakamae, Satoshi Yoshioka, Makoto Onizuka, Tatsuo Ichinohe, Yoshiko Atsuta, Shinichi Kako

研究成果: Contribution to journalArticle査読

抄録

Allogeneic haematopoietic stem cell transplantation (allo-HSCT) is one of the curative treatment options for acute lymphoblastic leukaemia (ALL). However, the outcomes in patients transplanted without complete remission (non-CR) have not yet been fully reported, and detailed analyses are required to identify subgroups in which optimal prognosis is expected and to optimize pre-transplant therapeutic strategies. Hence, we performed a multicentred retrospective cohort study including a total of 663 adult ALL patients transplanted at non-CR status; the median bone marrow (BM) blast counts at HSCT was 13·2%, and 203 patients (30·6%) were treated at primary induction failure status. The overall survival (OS) was 31·1% at two years, and the multivariate analyses identified five prognostic risk factors, including older age (≥50 years), increased BM blasts (≥10%), poor performance status, high haematopoietic cell transplantation (HCT)-comorbidity index, and relapsed disease status, among which BM blast was the most significantly related. A predictive scoring system composed of these risk factors clearly stratified OS (15·6–59·5% at two years). In conclusion, this is the first large-scale study to analyze the correlation of patient characteristics with post-transplant prognosis in ALL transplanted at non-CR status. The importance of blast control before HSCT should be focused on for better patient prognosis.

本文言語英語
ページ(範囲)403-413
ページ数11
ジャーナルBritish Journal of Haematology
194
2
DOI
出版ステータス出版済み - 7 2021

All Science Journal Classification (ASJC) codes

  • 血液学

フィンガープリント

「Residual disease is a strong prognostic marker in patients with acute lymphoblastic leukaemia with chemotherapy-refractory or relapsed disease prior to allogeneic stem cell transplantation」の研究トピックを掘り下げます。これらがまとまってユニークなフィンガープリントを構成します。

引用スタイル